--- schema_version: "secwatch.filing_event.v1" accession: "0001213900-22-079522" form_type: "8-K" ticker: "HOTH" cik: "0001711786" company_name: "Hoth Therapeutics, Inc." filed_at: "2022-12-13T23:59:59+00:00" generated_at: "2026-06-21T05:32:01.129557+00:00" event_type: "leadership" sentiment: "neutral" materiality_score: 0.55 calibrated_materiality_score: 0.55 confidence: "high" source: SEC EDGAR --- # Hoth Therapeutics appoints Dr. Jeff Pavell to board; CSO Stefanie Johns departs; shares authorized to 50M ## Summary - Board expanded to five members; Dr. Jeff Pavell appointed Dec 7, 2022, and joins compensation committee. - CSO Stefanie Johns employment terminated Dec 9, 2022; receives 6 months base salary and benefit continuation. - Dr. Johns appointed to Scientific Advisory Board effective Dec 12, 2022. - Shareholders approved increase in authorized common shares from 3M to 50M at Dec 12 special meeting. - Vote: 11,881,817 for, 8,665,496 against, 3,690 abstain; amendment filed Dec 13. ## SEC filing metadata - accession: 0001213900-22-079522 - form_type: 8-K - ticker: HOTH - cik: 0001711786 - company_name: Hoth Therapeutics, Inc. - filed_at: 2022-12-13T23:59:59+00:00 - event_type: leadership - sentiment: neutral - materiality_score: 0.55 - calibrated_materiality_score: 0.55 - confidence: high - sec_items: 5.02, 5.03, 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1711786/000121390022079522/0001213900-22-079522-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711786/000121390022079522/ea170029-8k_hoththera.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001213900-22-079522 - JSON: https://secwatch.observer/filing/0001213900-22-079522.json - Plain text: https://secwatch.observer/filing/0001213900-22-079522.txt ## Key facts - Executive change Stefanie Johns was appointed as Scientific Advisory Board member at Hoth Therapeutics, Inc.. - Action: joined - Role: Scientific Advisory Board member source text: On December 12, 2022, Dr. Johns joined the Company’s Scientific Advisory Board and will continue to consult and monitor the Company’s pipeline development in such role. evidence_url: https://www.sec.gov/Archives/edgar/data/1711786/000121390022079522/0001213900-22-079522-index.htm - Executive change Jeff Pavell was appointed as member of the Board at Hoth Therapeutics, Inc.. - Action: appointed - Role: member of the Board source text: On December 7, 2022, the board of directors (the “Board”) of Hoth Therapeutics, Inc. (the “Company”) increased the size of the Board to five members and appointed Jeff Pavell, D.O., as a member of the Board to fill the vacancy created by the increase in the size of the Board. evidence_url: https://www.sec.gov/Archives/edgar/data/1711786/000121390022079522/0001213900-22-079522-index.htm - Executive change Stefanie Johns departed as Chief Scientific Officer at Hoth Therapeutics, Inc.. - Action: ceased - Role: Chief Scientific Officer source text: On December 9, 2022 (the “Separation Date”), the employment of Stefanie Johns as Chief Scientific Officer of the Company ceased. evidence_url: https://www.sec.gov/Archives/edgar/data/1711786/000121390022079522/0001213900-22-079522-index.htm - Governance Changes Hoth Therapeutics, Inc.: 公司章程修正案将授权普通股从3,000,000股增加到50,000,000股 (effective 2022-12-13). - Change: charter amendment - Effective: 2022-12-13 source text: On December 13, 2022, the Company filed a Certificate of Amendment (the “Amendment”) to its Articles of Incorporation, as amended, to increase its authorized shares of common stock from 3,000,000 shares to 50,000,000 shares. evidence_url: https://www.sec.gov/Archives/edgar/data/1711786/000121390022079522/0001213900-22-079522-index.htm - Shareholder Votes Hoth Therapeutics, Inc. shareholders approved increase to the number of authorized shares of the Company’s common stock from 3,000,000 shares to 50,000,000 shares at the 2022-12-12 meeting. - Proposal: charter amendment - Outcome: passed - Meeting: 2022-12-12 source text: On December 12, 2022, the Company held its 2022 special meeting of shareholders (the “Special Meeting”) for the purpose holding a shareholder vote on Proposal 1 set forth below. A total of 551,003 shares of the Company’s common stock and 2,000,000 shares of the Company’s Series B Preferred Stock, constituting a quorum, were represented in person or by valid proxies at the Special Meeting. As previously described in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on November 14, 2022 (the “Proxy Statement”), the holder of record of the 2,000,000 outstanding shares of the Company’s Series B Preferred Stock was entitled to 20,000,000 votes, had the right to vote only on Proposal 1, and such votes were counted in the same proportion as the shares of the Company’s common stock voted on Proposal 1. Holders of the Company’s common stock were entitled to one vote per share on Proposal 1. Proposal 1 . At the Special Meeting, the shareholders approved a evidence_url: https://www.sec.gov/Archives/edgar/data/1711786/000121390022079522/0001213900-22-079522-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.